36950-43-3

Upstream product

• 53905-19-4 (E)-2-styrylquinazolin-4(3H)-one 

Downstream Products

• 78222-36-3 N-(2-styryl-4-quinazolinyl)-N'-benzoylhydrazine 
• 78222-31-8 3-Methyl-5-((E)-styryl)-[1,2,4]triazolo[4,3-c]quinazoline 
• 78222-30-7 5-((E)-Styryl)-[1,2,4]triazolo[4,3-c]quinazoline 
• 78222-34-1 2-styryl-4-hydrazinoquinazoline 

Relevant academic research and scientific papers

Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities

Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2- phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP- PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3- pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.

Synthesis of some 2-styrylquinazoline derivatives structurally related to certain chemotherapeutic agents.

The synthesis of certain 2-styryl-4-arylaminoquinazolines having the general formula 1 is described. 4-Chloro-2-styrylquinazolines were prepared by chlorination of 2-styryl-4-quinazolones in benzene solution using phosphorus oxychloride and an excess of dimethylaniline. Reacting the chlorostyrylquinazolines with certain arylamines afforded 1.